35.73

0.78% -0.28

Teva Pharmaceutical Industries Ltd Adr (TEVA)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt TEVA? Forum Prognose Aktiensplit Dividendenhistorie

Schlusskurs vom Vortag:

$36.01

Offen:

$36.26

24-Stunden-Volumen:

8.22M

Relative Volume:

1.17

Marktkapitalisierung:

$41.60B

Einnahmen:

$17.53B

Nettoeinkommen (Verlust:

$1.58B

KGV:

26.55

EPS:

1.3457

Netto-Cashflow:

$444.18M

1W Leistung:

+2.23%

1M Leistung:

+17.07%

6M Leistung:

+49.06%

1J Leistung:

+97.73%

1-Tages-Spanne:

$35.43

$36.33

1-Wochen-Bereich:

$35.02

$36.99

52-Wochen-Spanne:

$14.99

$37.34

Teva Pharmaceutical Industries Ltd Adr Stock (TEVA) Company Profile

Firmenname

Teva Pharmaceutical Industries Ltd Adr

Sektor

Healthcare (1111)

Branche

Drug Manufacturers - Specialty & Generic (84)

Telefon

972 (3) 914-8213

Adresse

TEVA PHARMACEUTICAL INDUSTRIES LIMITED, TEL AVIV

Mitarbeiter

32,842

Twitter

@TevaUSA

Nächster Verdiensttermin

2026-04-29

Neueste SEC-Einreichungen

TEVA's Discussions on Twitter

Compare TEVA vs TAK, HLN, ZTS, UTHR

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
TEVA Teva Pharmaceutical Industries Ltd Adr	35.73	41.60B	17.53B	1.58B	444.18M	1.3457
TAK Takeda Pharmaceutical Co Adr	16.46	52.00B	29.85B	776.90M	4.35B	0.2408
HLN Haleon Plc Adr	9.11	40.43B	14.54B	2.22B	2.58B	0.4871
ZTS Zoetis Inc	82.83	34.72B	9.47B	2.67B	2.28B	6.0218
UTHR United Therapeutics Corp	564.94	23.98B	3.18B	1.33B	1.04B	27.90

Teva Pharmaceutical Industries Ltd Adr Stock (TEVA) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-12-09	Eingeleitet	Barclays	Overweight
2025-12-05	Eingeleitet	Scotiabank	Sector Outperform
2025-06-06	Eingeleitet	Goldman	Buy
2025-05-28	Eingeleitet	Truist	Buy
2025-05-12	Hochstufung	JP Morgan	Neutral → Overweight
2024-07-10	Hochstufung	Argus	Hold → Buy
2024-03-08	Hochstufung	JP Morgan	Underweight → Neutral
2024-02-12	Hochstufung	Piper Sandler	Neutral → Overweight
2024-01-23	Hochstufung	Jefferies	Hold → Buy
2024-01-03	Hochstufung	Piper Sandler	Underweight → Neutral
2023-12-18	Eingeleitet	HSBC Securities	Buy
2023-11-27	Hochstufung	UBS	Neutral → Buy
2023-07-06	Hochstufung	UBS	Sell → Neutral
2023-05-25	Eingeleitet	Morgan Stanley	Equal-Weight
2023-05-18	Hochstufung	Evercore ISI	In-line → Outperform
2023-01-19	Herabstufung	Jefferies	Buy → Hold
2022-11-14	Herabstufung	JP Morgan	Neutral → Underweight
2022-11-04	Herabstufung	UBS	Neutral → Sell
2022-10-21	Fortgesetzt	Jefferies	Buy
2022-08-05	Hochstufung	BofA Securities	Neutral → Buy
2022-06-14	Fortgesetzt	UBS	Neutral
2022-05-17	Hochstufung	BofA Securities	Underperform → Neutral
2022-05-04	Herabstufung	Piper Sandler	Neutral → Underweight
2022-04-05	Hochstufung	Barclays	Equal Weight → Overweight
2022-03-25	Hochstufung	Bernstein	Mkt Perform → Outperform
2022-01-27	Herabstufung	Argus	Buy → Hold
2021-10-28	Herabstufung	Raymond James	Outperform → Mkt Perform
2021-05-04	Herabstufung	UBS	Buy → Neutral
2021-04-07	Fortgesetzt	RBC Capital Mkts	Sector Perform
2020-11-25	Eingeleitet	Oppenheimer	Perform
2020-08-06	Hochstufung	Barclays	Underweight → Equal Weight
2020-07-27	Fortgesetzt	Goldman	Neutral
2020-06-01	Hochstufung	SunTrust	Hold → Buy
2020-04-24	Fortgesetzt	Citigroup	Neutral
2020-04-06	Hochstufung	UBS	Neutral → Buy
2020-02-24	Herabstufung	Edward Jones	Hold → Sell
2019-11-12	Hochstufung	JP Morgan	Underweight → Neutral
2019-10-17	Hochstufung	Gabelli & Co	Hold → Buy
2019-08-07	Herabstufung	Evercore ISI	Outperform → In-line
2019-07-19	Eingeleitet	Wolfe Research	Peer Perform
2019-07-15	Herabstufung	Morgan Stanley	Equal-Weight → Underweight
2019-07-10	Fortgesetzt	Credit Suisse	Neutral
2019-07-05	Hochstufung	Argus	Hold → Buy
2019-06-11	Eingeleitet	Barclays	Underweight
2019-06-03	Hochstufung	Oppenheimer	Perform → Outperform
2019-05-30	Herabstufung	BofA/Merrill	Buy → Underperform
2019-05-28	Herabstufung	UBS	Buy → Neutral
2019-03-20	Eingeleitet	SunTrust	Hold
2019-03-07	Fortgesetzt	UBS	Buy

Alle ansehen

Teva Pharmaceutical Industries Ltd Adr Aktie (TEVA) Neueste Nachrichten

May 08, 2026

A Look At Teva Pharmaceutical Industries (NYSE:TEVA) Valuation After Strong Q1 2026 And Biopharma Pipeline Progress - Sahm

May 08, 2026

May 06, 2026

Is It Too Late To Reassess Teva Pharmaceutical Industries (TEVA) After Its Strong Multi Year Rally? - Sahm

May 06, 2026

May 05, 2026

Reddit Upgraded, Spotify Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace

May 05, 2026

May 04, 2026

Teva to Present at the BofA Securities Health Care Conference - Sahm

May 04, 2026

May 03, 2026

Why Teva (TEVA) Is Up 14.1% After Strong Q1 Profitability And Neuroscience Pivot News - Sahm

May 03, 2026

May 01, 2026

Teva Pharmaceutical (TEVA) Q1 EPS Of US$0.32 Tests Bullish Profitability Narrative - Sahm

May 01, 2026

Apr 30, 2026

Teva Signals Confidence With $700 Million Pipeline Push, Buyback Plan - Sahm

Apr 30, 2026

Teva Pharmaceutical Indus Q1 2026 Earnings Call Transcript - Sahm

Apr 30, 2026

Teva’s 2025 Healthy Future Report Highlights Environmental and Access to Medicines Progress, Including Meeting All Sustainability-Linked Bond Targets - Sahm

Apr 30, 2026

Apr 29, 2026

Teva’s Home Ground Schizophrenia Push And What It Could Mean For Investors - Sahm

Apr 29, 2026

Teva Signals Confidence With $700 Million Pipeline Push, Buyback Plan - Benzinga

Apr 29, 2026

Teva Enjoys Strong Start to 2026 Thanks to Strong Momentum in Branded Portfolio - Morningstar

Apr 29, 2026

Earnings call transcript: Teva beats Q1 2026 forecasts, stock surges 7.5% - Investing.com

Apr 29, 2026

Apr 27, 2026

Intel Upgraded, Toyota Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace

Apr 27, 2026

Apr 23, 2026

Dermatomycoses Market Report 2025-2035, Profiles of Prominent Players - GlobeNewswire Inc.

Apr 23, 2026

Apr 22, 2026

Is It Too Late To Reassess Teva (TEVA) After Its 118.5% One-Year Surge? - Sahm

Apr 22, 2026

Apr 19, 2026

Assessing Teva Pharmaceutical Industries (NYSE:TEVA) Valuation After The Home Ground Schizophrenia Platform Launch - Sahm

Apr 19, 2026

Apr 18, 2026